Cancer clinical trial recruitment for patients from rural areas: a scoping review Authors: Patrick O’Donnell, Rose Galvin, Katie Robinson, Peter Hayes, Ruth Clifford, Niamh Peters, Deirdre Hartigan, Sarah Dillon Published: 2026 ABSTRACT AbstractBackgroundThis work will explore the literature on recruiting patients from rural and remote areas to cancer clinical trials. By examining the definitions employed, identifying levers and barriers to recruitment, and describing initiatives to promote recruitment, we seek to inform the development of future trials with these populations.MethodsA scoping review of primary research published since 2004 relating to the recruitment of patients from rural or remote areas to cancer clinical trials was conducted. The cancer could be of any type, haematological or solid tumour. A comprehensive literature search was conducted in CINAHL, PsycINFO, PubMed/MEDLINE, C2-SPECTR Campbell Systematic Reviews and Cochrane Library. All records were screened by two independent reviewers, and data on study characteristics and findings were extracted and analysed.ResultsA total of 29,160 papers were identified in the searches. After screening, 27 studies met our inclusion criteria. Twenty-three of those papers focused on the context of the United States of America, with an additional three looking at Australia and one at Canada. There was no uniformity in researchers’ classification of rurality, despite the existence of agreed measures. Several common levers and barriers to engagement were identified, including the distances patients must travel to cancer centres.ConclusionsRurality is a significant challenge to the recruitment of cancer patients to clinical trials. The potential solutions are multifaceted and span the major determinants of health. Focus on the development of collaborative research networks between major academic cancer centres and rural healthcare facilities may help improve access to trials.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12939-026-02904-0.Keywords: Cancer, Clinical trials, Recruitment, Equity, Rural health, Scoping review Introduction Background Cancer incidence is rising worldwide, with modelling predicting that the number of new cases diagnosed annually will reach 35 million patients by 2050, significantly more than the estimated 20 million patients diagnosed in 2022 [1]. In response to these increases, there is a constant need for innovation in the development of new ways of treating cancers. Clinical trials (CT) are essential for evaluating new therapies and improving patient outcomes, while also providing valuable information for managers, policymakers and commercial entities [2]. However, less than 8% of adult cancer patients in the United States of America (USA) participate in trials, and the profile of participants often does not reflect the general population [3]. In Europe, fragmented healthcare systems and use of a number of different trial registries make estimating cancer trial participation rates difficult [4]. This has implications for the generalisability of trial findings and the confidence of clinicians in employing novel treatments with some underrepresented groups [5]. A lack of diversity among clinical trial participants can lead to varying treatment responses across different population groups due to their physiology or disease profile, complicating risk-benefit assessments [5]. Understanding and addressing both structural and clinical barriers to trial participation is crucial for enhancing enrolment among cancer patients [2]. Work to make cancer CT more equitable and representative has become more prominent internationally in recent years [6, 7]. For example, in 2020, the American Society of Clinical Oncology released a policy statement examining equity issues across the cancer continuum, and reaffirming their commitment to achieving “equitable access to care, improving clinical research, addressing structural barriers, and increasing awareness that results in measurable and timely action toward achieving cancer health equity for all” [8, p. 3439]. In the United Kingdom (UK), the National Institute for Health Research created the ‘Innovations in Clinical Trial Design and Delivery for the Under-served’ (INCLUDE) project has begun to systemically identify barriers and provide trialists with knowledge and tools for overcoming those barriers [5]. Internationally, there is more focus on improving the representation of underserved groups in cancer research across the continuum from diagnosis to treatment [6, 9–15]. Warner et al. have succinctly defined equity in this context as “acknowledging sociodemographic circumstances and apportioning resource and opportunity allocation to eliminate disparities in outcomes” [16, p. 8]. The classification of ‘underserved groups’ varies, with Crossley and Baybutt describing them as groups that “have limited access to healthcare, experience significant health disparities globally due to various intersecting factors, including race, ethnicity, socioeconomic status, geographic location, gender identity, disability, sexual orientation and setting” [17, p. 341]. Rural-urban disparities in cancer treatment and outcomes are increasingly recognised [18–20]. These differences stem from multiple factors, including inadequate clinical infrastructure, low health insurance coverage, transportation challenges, higher smoking rates, lack of information, and, importantly, barriers to clinical trial participation [21]. In Europe there is acknowledgement that rurality and geographical inequities are a concern in the context of making clinical trials accessible to all cancer patients [4]. There is also a marked difference between the number of trials taking place in Western Europe versus Central and Eastern Europe which are underserved in this regard [22]. This scoping review builds on the foundational work of Ford et al., who examined barriers to cancer CT enrolment among underrepresented groups, looking at awareness, participation opportunities and the decision-making process regarding trial involvement [23]. Of the 65 studies Ford included, it is notable that only three focused on rural physicians or cancer trial participants [23]. A more recent review by McPhee et al. identified 24 studies in 2020 and reported on potential barriers or enablers of CT participation among rural participants, some of whom did not have cancer [24]. Given the growth in publications on this topic in the intervening years, an updated synthesis of the evidence is warranted. We noted that many reviews have included papers in which some participants themselves did not have cancer or a history of cancer. They were often asked hypothetically about potential engagement in cancer CT. Whilst unaffected participants may provide useful insights on certain aspects of care such as the user-friendliness of trial materials, their lack of lived experience of cancer may affect the resulting conclusions. Initially, we aimed to examine all underserved groups, but we subsequently agreed to focus on rural and remote populations only for this review. Rural cancer patients often experience major challenges in accessing trials, and the nuances of these barriers warrant deeper analysis [6, 25, 26]. Defining ‘rural’ itself is complex, and the United States Census Bureau, the United Nations, the World Bank and others have all sought to clarify it for inclusion in policy and research [27]. The varying definitions can also be limited in applicability outside of their country of origin as they often incorporate specific geographic factors or population indicators. The size of the rural population in the USA is significant, with the Federal Office of Rural Health Policy estimating that 87.4% of the land in the USA was rural and 20.3% of the population (62.8 million people) were rurally based in 2020, similar to the 20.6% of EU rural inhabitants estimated in 2023 [28, 29]. Therefore, this scoping review aimed to understand the extent and type of evidence published in relation to the recruitment of adults with cancer living in rural or remote areas to CT. This included the objectives of exploring the definitions of rural status used by researchers, analysing the factors that may have promoted or impeded recruitment and describing some of the recruitment initiatives employed by trialists. Methods Study design This scoping review was conducted in accordance with the JBI guidelines, and we adhered to the PRISMA Scoping Review checklist (Related File 1) to support rigorous conduct and reporting of the review [30, 31]. The protocol for the work was published on PROSPERO, and it was planned to include all underserved groups and conduct a rapid review (CRD42024518076). We subsequently decided to focus on people living in rural and remote areas only, and to convert to a scoping review as the papers we discovered were more diverse in methodology than anticipated. The research question, inclusion and exclusion criteria, and databases searched remained unchanged from the protocol. This change aligned with our revised aim of mapping the available literature focused on the recruitment of adults with cancer to CT in rural or remote settings. It also reflects that rurality is a factor of paramount importance in healthcare disparities in the USA and around the world [32, 33], and differences in cancer outcomes in particular [34]. In line with scoping review methodology, we did not appraise the quality of included papers [35]. As the work was a desk-based review of published research, no research ethics committee approval was required. Inclusion criteria Criteria were developed using the JBI population, concept and context approach. Sources were included if they met the following criteria: they were peer-reviewed research articles published in English since 2004, focusing on the recruitment of adult patients with any type of cancer for CT related to that diagnosis. We decided on a 20-year timeframe (2004–2024) to ensure that the evidence analysed would be contemporary while also capturing changes in clinical trial design and recruitment practices over time. Qualitative, quantitative, and mixed-methods studies, as well as evidence synthesis papers, were eligible for inclusion. Research focusing on children or the experiences of patients without cancer was excluded. Additionally, commentary papers, editorials, book chapters, theses, and news articles were excluded. For a paper to be eligible, it had to explicitly mention a rural or remote context in the title or abstract. Studies with mixed participant groups (e.g. rural and urban) were included only if more than half of the participants were from rural or remote areas or if the results for rural or remote participants were reported separately. Selecting studies A search was conducted in February 2024, updated in January 2025, across five databases: CINAHL, PsycINFO, PubMed/MEDLINE, C2-SPECTR and the Cochrane Library. The search strategy is detailed in Additional File 1. The online review management software Rayaan was used to de-duplicate and screen all papers (ww.rayyan.ai). Initially, the title and abstract of each paper were reviewed by two independent researchers, and then the full text of all relevant papers was scrutinised by the two same independent researchers. Any conflicting decisions were brought to regular research meetings where four researchers examined the papers, and a consensus was reached. The results of this process are detailed in Figure 1 below. For evidence synthesis papers, we took the component papers and applied our inclusion and exclusion criteria to them; we then removed the ‘parent’ evidence synthesis paper. PRISMA diagram Charting data and reporting Data were extracted from each paper into a Microsoft Excel file with tailored categories. A narrative analysis of research findings was instead conducted, and results are reported in a series of tables. Studies that addressed psychosocial factors affecting rural patient participation in cancer CT were further analysed using the Social Ecological Model (SEM) previously adapted by Wells and Zebrack to examine cancer CT participation of underserved patients [36–38]. This approach was chosen for its nuance in categorising barriers relevant to our analysis. Their original categories included inTRApersonal, inTERpersonal, environment, community, sociocultural and institutional factors, and we adapted it by adding a seventh category of patient characteristics and by using it to explore enablers as well as barriers (see Table 1). Table 1Categorisation of levers and barriersCategoryBrief explanationInTRApersonalConcerns the individual and their reasoning around taking part.InTERpersonalLooks at the influence of others on the decisions of an individual.EnvironmentalReferences the context in which a person lived.SocioculturalLooks at the influence of culture on decision-making.CommunityConsiders the work of researchers and communities to support engagement.InstitutionalFocuses on structural barriers that could prevent engagement.Patient characteristicsConsiders the condition of an individual and their strengths as integral components of the decision-making process Categorisation of levers and barriers These categories were not applied to papers focused on specific interventions or initiatives, or those exploring some aspects of patient decision making and knowledge of cancer trials, as these topics did not align with the scope of their analytic lens [38]. Papers focused on those aspects of clinical trial research are based on specific gaps already identified in the literature or practice. Public and patient involvement The idea for this evidence synthesis was derived from engagement with a Public and Patient Involvement (PPI) stakeholder group of older adults and family caregivers recruited from across the Mid-West region of Ireland. This geographical region comprises a mix of urban and rural areas where distance and access to healthcare have been reported as problematic. This PPI panel has previously participated in several health service research projects. Participation in CT was discussed with approximately 20 panel members at a two-hour meeting in May 2025. Discussion was facilitated by co-authors to explore pertinent issues, including the logistics of healthcare access from rural areas, including travel time, costs, availability of family members to support with appointments and the limited availability of public transport. Overall, there was agreement by the PPI panel with the interpretation of findings presented in this scoping review. Strategies suggested to potentially overcome these barriers included subsidised travel, adequate notification of appointments, integration of care and pooled resources to alleviate travel costs. Results General results A total of 29,160 records were identified through database searches. After screening, 27 studies met the inclusion criteria, and the PRISMA flow diagram (Fig. 1) provides an overview of the study selection process. The 27 papers included in Table 2 comprise fourteen quantitative, nine qualitative and four mixed methods papers. Twenty-three of the papers were looking at the USA, while three examined the Australian context [41, 60] and one focused on Canada [39]. Eighteen papers focused on the rural context exclusively, while nine authors included participants from both rural and non-rural areas. Some were included as a direct comparator group, e.g. rural versus urban [43, 64], with others examining rural participants with participants from other underserved groups, such as ethnic minorities [46, 47, 51, 59]. Table 2General resultsFirst Author & YearTitleStudy designCountrySettingParticipant no rangeParticipant typeFocus1Wagoner CW [39]2023First-Year Implementation of the EXercise for Cancer to Enhance Living Well (EXCEL) Study: Building Networks to Support Rural and Remote Community Access to Exercise Oncology ResourcesQuantitative - cross-sectional survey, questionnaireCanadaRural100–999Cancer patientsEvaluating an exercise intervention for cancer patients – its reach, adoption and implementation2Virani S [40]2011Barriers to Recruitment of Rural Patients in Cancer Clinical TrialsQuantitative - cross-sectional survey, questionnaireUSARural100–999Cancer patientsExploring barriers to participation of rural patients in cancer CT3Sabesan S [41]2011Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patientsQuantitative - cross-sectional survey, questionnaireAustraliaRural100–999Cancer patientsExploring attitudes, knowledge and barriers to participation of rural patients in cancer CT4Pathak S [42]2019Evaluating Adaptation of a Cancer Clinical Trial Decision Aid for Rural Cancer Patients: A Mixed-Methods ApproachMixed methods – qualitative interviews on usability, followed by pre & post quantitative surveyUSARural1–49Cancer patientsAdapting cancer CT decision aid for rural patients and testing to assess impact on knowledge and decision outcomes5Mudaranthakam DP [43]2022Barriers to Clinical Trial Participation: Comparative Study Between Rural and Urban ParticipantsQuantitative – cross-sectional study on clinic dataUSARural & Urban1000–4999Cancer patientsComparing barriers to participation of rural and urban patients in cancer CT6Krieger JL [44]2015Comprehension of Randomization and Uncertainty in Cancer Clinical Trials Decision Making Among Rural, Appalachian PatientsMixed methods – qualitative interviews on usability, followed by quantitative surveyUSARural & Urban1–49Cancer patientsExploring patients understanding of randomisation, treatment uncertainty and willingness to enrol in cancer CT7Krieger JL [45]2014Last resort or roll of the die? Exploring the role of metaphors in cancer clinical trials education among medically underserved populationsQualitative - semi-structured interviews & focus groupsUSARural1–49Carers & Cancer patientsExploring older, low-income female patients understanding of cancer CT by examining metaphors used in clinical encounters8Guadagnolo BA [46]2009Involving American Indians and medically underserved rural populations in cancer clinical trialsQuantitative - prospective, observational cohort studyUSARural100–999Cancer patientsExploring barriers to participation of American Indian and rural patients in cancer CT9Geana M [47]2017Searching for cures: Inner-city and rural patients’ awareness and perceptions of cancer clinical trialsQualitative - semi-structured interviewsUSARural & Urban50–99Cancer patientsExploring patients understanding of cancer CT and their perceptions of healthcare providers communication about CT10Friedman DR [48]2024Veterans with blood cancers: Clinical trial navigation and the challenge of ruralityQuantitative - observational studyUSARural & Urban1–49Clinicians & Cancer patientsExploring how living rurally influences cancer CT engagement by veterans with blood cancers11Farris P [49]2023Rural research capacity: a co-created model for research successQualitative – participatory implementation science studyUSARural1–49Community leaders, healthcare providers, patients and public health championsDeveloping a tool with community members for researchers to use to promote uptake of cancer CT in rural areas12Ellis SD [50]2019Science in the Heartland: Exploring determinants of offering cancer clinical trials in rural-serving community urology practicesQualitative - semi-structured interviewsUSARural1–49CliniciansExploring the factors that urologists working in rural areas consider when referring to cancer CT13Ellis S [51]2019Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practicesMixed methods – qualitative stakeholder engagement, followed by collection of quantitative dataUSARural & Urban1–49CliniciansDeveloping an intervention to promote the referral of urology cancer patients to CT using implementation science approach14Coyne CA [52]2004Rural cancer patients’ perspectives on clinical trials: a qualitative studyQualitative – interviewsUSARural1–49Cancer patientsExploring attitudes and perspectives of rural patients to cancer CT15Borno HT [53]2018At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical TrialsQuantitative – retrospective observational studyUSARural & Urban1000–4999Cancer patientsDescribing the travel burden of rural patients on cancer CT16Befort CA [54]2015Effective recruitment of rural breast cancer survivors into a lifestyle interventionQuantitative – prospective observational studyUSARural100–999Cancer patientsDescribing effectiveness of variety of recruitment methods for cancer CT focused on lifestyle intervention17Cupertino AP [55]2015Empowering Promotores de Salud as partners in cancer education and research in rural southwest Kansas.Quantitative - in-person interviews pre-training, and telephone follow-up interviewsUSARural1–49Community health workersDeveloping and evaluating training on cancer and CT for rural community workers18Elliott TE [56]2004Improving rural cancer patients’ outcomes: a group-randomized trial.Quantitative – randomised controlled trialUSARural1000–4999Clinicians & Cancer patientsEvaluating to impact of an intervention for healthcare professionals on outcomes for rural cancer patients19Krieger JL [57]2017Distributed cognition in cancer treatment decision making: an application of the DECIDE decision-making styles typology.Qualitative – semi-structured interviewsUSARural1–49Cancer patientsExploring the decision making of rural cancer patients and their caregivers when engaging with cancer CT20Riggs MJ [58]2022Factors predicting participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky.Quantitative – prospective observational cohort studyUSARural & Urban1000–4999Cancer patientsExploring the participation of rural cancer patients in cancer genomic sequencing in Kentucky21Tanner A [59]2015Promoting clinical research to medically underserved communities: current practices and perceptions about clinical trial recruitment strategies.Quantitative – online surveyUSARural & Urban1–49Researchers & CliniciansExploring how cancer CT researchers try to recruit rural participants22Zdenkowski N [60]2019Results of a survey of cancer patients’ willingness to travel to participate in a clinical trial.Quantitative – online or in-person surveyAustraliaRural100–999Cancer patientsExploring the factors influencing cancer patients decisions to travel to take part in CT23Arana-Chicas E [61]2025Barriers to participation in clinical trials of rural older adult cancer survivors: A qualitative studyQualitative – semi-structured interviewsUSARural1–49Cancer patientsExploring the barriers to participation of rural older adult cancer patients in CT24Kumar A [62]2024Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United StatesQuantitative – prospective observational study on patient data and provider surveyUSARural100–999Cancer patientsExploring the barriers to participation of rural cancer patients in molecular tumour boards25Kohut M [63]2025Potential Barriers to Participating in Cancer Moonshot Biobank for Low-Income Patients with Cancer of Rural MaineQualitative – semi-structured interviewsUSARural1–49Clinicians, Researchers & Cancer patientsAnalysing participation in the National Cancer Institute Cancer Moonshot Biobank by rural, low-income cancer patients in Maine26Lent M [64]2025Differences in rural and urban patient perceptions of facilitative factors for cancer clinical trial participationMixed methods – interviews with some items analysed quantitatively and some qualitativelyUSARural & Urban1–49Cancer patientsExploring the factors that influence CT participation for rural versus urban-based patients27McPhee N [65]2025“It’s a reasonable gamble”—rural residents’ experience participating in cancer clinical trials at a single rural trial unitQualitative – semi-structured interviewsAustraliaRural1–49Cancer patientsLooking at the factors that determine whether rural cancer patients enrol on CTs, and what their retention on those CTs General results Wagoner CW [39] 2023 Virani S [40] 2011 Sabesan S [41] 2011 Pathak S [42] 2019 Mudaranthakam DP [43] 2022 Krieger JL [44] 2015 Krieger JL [45] 2014 Guadagnolo BA [46] 2009 Geana M [47] 2017 Friedman DR [48] 2024 Farris P [49] 2023 Ellis SD [50] 2019 Ellis S [51] 2019 Coyne CA [52] 2004 Borno HT [53] 2018 Befort CA [54] 2015 Cupertino AP [55] 2015 Elliott TE [56] 2004 Krieger JL [57] 2017 Riggs MJ [58] 2022 Tanner A [59] 2015 Zdenkowski N [60] 2019 Arana-Chicas E [61] 2025 Kumar A [62] 2024 Kohut M [63] 2025 Lent M [64] 2025 McPhee N [65] 2025 Eighteen papers examined the experiences of patients with a current or past history of cancer, two analysed the experiences of clinicians [50, 51], two looked at patients and clinicians together [48, 56], one looked at cancer patients and carers [45], one focused on community health workers [55], one looked at a mixture of community leaders and others [49], one explored the views of researchers and clinicians [59], and one looked at clinicians, researchers and cancer patients together [65]. Not surprisingly, distance and the onerous travel often required to partake in CT emerged as key barriers in five studies [48, 53, 56, 60, 64], with seven other papers highlighting some aspects of travel-related challenges [40, 43, 52, 61–63, 65]. Friedman et al. described the existence of “clinical trial deserts” in certain parts of the USA [48], (p114) while Borno et al. found that participants from more deprived areas were travelling longer distances to trial centres than wealthier participants (58.3 versus 17.8 miles) [53]. Zdenkowski et al. surveyed cancer patients about their willingness to take part in CT, finding that many of them were willing to travel significant distances to engage with a new clinical team if it allowed them to enrol on a suitable trial [60]. Definitions There was heterogeneity across the included studies in the definitions applied to classify the rurality of participants. These are listed in Table 3. Table 3DefinitionsNoFirst AuthorTitleCountryDefinition/characterisation of rural1Wagoner CW [39]First-Year Implementation of the EXercise for Cancer to Enhance Living Well (EXCEL) StudyCanadaEligibility for the research included people living in underserved rural or remote communities (population < 100,000 people) & links to a document on Developing Meaningful Categories for Distinguishing Levels of Remoteness in Canada http://www150.statcan.gc.ca/n1/en/pub/11-633-x/11-633-x2020002-eng.pdf?st=-C6R8DT12Virani S [40]Barriers to Recruitment of Rural Patients in Cancer Clinical TrialsUSAParticipants were considered rural as they attended a cancer centre in West Virginia; also, clinics documented zip codes but did not report if, or how many, participants were rural or what criteria were used. In the Discussion section, it details the US Census Bureau rural classification and states that 63.8% of West Virginia’s population is rural as a result.3Sabesan S [41]Attitudes, knowledge and barriers to participation in cancer clinical trials among rural and remote patientsAustraliaRurality was defined according to the Australian Institute of Health and Welfare 2004 classification that categorised areas into groups based on population size https://nla.gov.au/nla.obj-721900852/view4Pathak S [42]Evaluating Adaptation of a Cancer Clinical Trial Decision Aid for Rural Cancer Patients: A Mixed-Methods ApproachUSAPhase 1 and 2 participant inclusion criteria mentioned living in a zip code with a Rural-Urban Commuting Area code (RUCA) indicating they lived in a small rural town.5Mudaranthakam DP [43]Barriers to Clinical Trial Participation: Comparative Study Between Rural and Urban ParticipantsUSACommunity site information was noted, including the county and state they were located in and the Rural Urban Continuum Codes (RUCC) which would show whether they were rural or urban depending on population and urbanization.6Krieger JL [44]Comprehension of Randomization and Uncertainty in Cancer Clinical Trials Decision Making Among Rural, Appalachian PatientsUSADid not define, but patients lived in or were treated for cancer in one of 32 Appalachian counties in Ohio.7Krieger JL [45]Last resort or roll of the die? Exploring the role of metaphors in cancer clinical trials education among medically underserved populationsUSAThe home address of patients was in a county designated as rural by the Center for Rural Pennsylvania.8Guadagnolo BA [46]Involving American Indians and medically underserved rural populations in cancer clinical trialsUSAUsed the US Index of Medical Underservice to flag Western South Dakota where the study was taking place as underserved and then deeming all patients presenting for evaluation at a Cancer Care Institute in that region as eligible.9Geana M [47]Searching for cures: Inner-city and rural patients’ awareness and perceptions of cancer clinical trialsUSADid not define, but participants from an inner-city and a rural oncology clinic in the US Midwest were recruited using network and convenience sampling techniques.10Friedman DR [48]Veterans with blood cancers: Clinical trial navigation and the challenge of ruralityUSADid not define, but researchers selected research facilities that served almost exclusively urban or rural populations.11Farris P [49]Rural research capacity: a co-created model for research successUSADid not define but includes extensive discussion about rural context.12Ellis SD [50]Science in the Heartland: Exploring determinants of offering cancer clinical trials in rural-serving community urology practicesUSADid not define but identified practices for inclusion by obtaining a list of urologists and excluding those in metropolitan counties.13Ellis S [51]Development, acceptability, appropriateness and appeal of a cancer clinical trials implementation intervention for rural- and minority-serving urology practicesUSADid not define but mentions engagement with rural-serving practices.14Coyne CA [52]Rural cancer patients’ perspectives on clinical trials: a qualitative studyUSAParticipants were living in rural areas defined by the US RUCC classification, and patients were recruited from eleven of West Virginia’s 55 counties giving broad geographical representation.15Borno HT [53]At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical TrialsUSADid not define but described a method for taking the cancer CT centre location and patient address to look at the travel distances involved.16Befort CA [54]Effective recruitment of rural breast cancer survivors into a lifestyle interventionUSADid not define but recruited by partnering with oncology clinics serving large percentages of rural patients.17Cupertino AP [55]Empowering Promotores de Salud as partners in cancer education and research in rural southwest Kansas.USADid not define but mentioned the setting for the research was rural communities in Kansas.18Elliott TE [56]Improving rural cancer patients’ outcomes: a group-randomized trial.USADescribes communities participating in the research as being designated as frontier, rural or urban using a US Census Bureau classification.19Krieger JL [57]Distributed cognition in cancer treatment decision making: an application of the DECIDE decision-making styles typology.USADid not define, but participants had to live in or seek treatment in one of 32 rural Appalachian counties in Ohio.20Riggs MJ [58]Factors predicting participation in the Prospective Genomic Sequencing Study, Total Cancer Care (TCC), in Kentucky.USAParticipants zip codes were used to ascertain RUCC status, and then their Appalachian status was categorised as Kentucky (KY) Appalachia, KY non-Appalachia and outside of KY.21Tanner A [59]Promoting clinical research to medically underserved communities: current practices and perceptions about clinical trial recruiting strategies.USADid not define but describes South Carolina as a state with a large rural-dwelling African American population and that 25/46 of its counties are designated as rural, with almost 40% of the population of the state living in rural areas.22Zdenkowski N [60]Results of a survey of cancer patients’ willingness to travel to participate in a clinical trial.AustraliaDid not define but reported that rurality was decided based on participants postcodes, but no definition of rural was given.23Arana-Chicas E [61]Barriers to participation in clinical trials of rural older adult cancer survivors: A qualitative studyUSAParticipants who were deemed to be rural lived at a zip code in an area that was deemed eligible for either a US Health Resources and Services Administration Federal Office of Rural Health Policy (FORHP) grant or a Center for Medicare and Medicaid Services Rural Health Clinics Program, and these were decided using the US Rural Health Information Hub ‘Am I rural?’ tool http://www.ruralhealthinfo.org/am-i-rural#/.24Kumar A [62]Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United StatesUSADid not define, but described participants as being engaged with community cancer clinics in rural areas.25Kohut M [63]Potential Barriers to Participating in Cancer Moonshot Biobank for Low-Income Patients with Cancer of Rural MaineUSAParticipants were living in or near non-metropolitan counties, defined by the US Office of Management and Budget (OMB) as containing no urbanised area with >50,000 residents26Lent M [64]Differences in rural and urban patient perceptions of facilitative factors for cancer clinical trial participationUSARural was defined using the Rural-Urban Commuting Area (RUCA) Codes (rural ≥ 4)27McPhee N [65]“It’s a reasonable gamble”—rural residents’ experience participating in cancer clinical trials at a single rural trial unitAustraliaParticipants were living in non-metropolitan areas as classified by the Monash Modified Model (MMM) grades 2–7 (i.e. rural, regional, remote). This approach categorised areas according to geographical remoteness and population size as per the Australian Bureau of Statistics. http://www.health.gov.au/topics/rural-health-workforce/classifications/mmm?language=und Definitions Thirteen of the 27 papers did not use any formal designation of participants; some used attendance at clinics in rural areas as a proxy identifier for the rural living status of their participants, others mentioned patients originating from predominantly rural regions or states, e.g. Appalachia, as an indicator of high likelihood of being rurally based. Five of the included papers from the USA mentioned the Rural–Urban Continuum Codes (RUCC) or Rural-Urban Commuting Area (RUCA) code classifications, which were developed by the United States (US) Department of Agriculture. The US Medically Underserved Area designation was mentioned by only one paper in our review [46], and another mentioned use of an online portal ‘Am I Rural’ [61]. One paper from Australia used an accepted national system of rural designation from that country [41], another used the Monash Modified Model [65], while the other Australian paper authors used postcodes but did not elaborate on what steps they took to stratify the rurality of the participants using those postcodes [60]. Wagoner et al. discussed the use of an adapted Canadian ‘remoteness index’ used to define inclusion in a rural population [39, 66]. Categorisation of levers and barriers Sixteen papers were analysed using the SEM as applied by Wells and Zebrack (Additional File 2) [36–38]. Among these, 12 studies focused on patients as participants, while 4 involved combinations that included clinicians and researchers. We systematically analysed each paper across the seven categories outlined previously, noting the presence of enablers and barriers for each category. Fourteen papers reported barriers or enablers in the inTRApersonal category. Enablers for trial participation included the belief that participating could extend their lives or provide access to novel treatments [40, 41]. Barriers included a lack of participant interest in taking part, a preference for standard treatment over experimental options, concerns about potential side effects from trial medications, and the belief that trial enrolment should be a last resort [41, 46–48, 58, 63]. Fourteen papers reported barriers or enablers in the inTRApersonal category. Enablers for trial participation included the belief that participating could extend their lives or provide access to novel treatments [40, 41]. Barriers included a lack of participant interest in taking part, a preference for standard treatment over experimental options, concerns about potential side effects from trial medications, and the belief that trial enrolment should be a last resort [41, 46–48, 58, 63]. Fourteen papers reported barriers and enablers that were categorised as inTERpersonal; relating to factors that can exert influence on an individual. Barriers included discouragement from enrolling by cancer clinicians, family physicians or family members, as well as concerns that clinicians may not have a full understanding of trials they were promoting [40, 41, 50, 58]. In contrast, enablers of trial participation included clinician encouragement, good relationships and communication with clinicians and hearing positive experiences of other patients on CT [41, 52, 59]. Fourteen papers reported barriers and enablers that were categorised as inTERpersonal; relating to factors that can exert influence on an individual. Barriers included discouragement from enrolling by cancer clinicians, family physicians or family members, as well as concerns that clinicians may not have a full understanding of trials they were promoting [40, 41, 50, 58]. In contrast, enablers of trial participation included clinician encouragement, good relationships and communication with clinicians and hearing positive experiences of other patients on CT [41, 52, 59]. Fifteen papers described environmental barriers that included the education and literacy levels of participants, socioeconomic status and the challenges of poverty, physical accessibility and the availability of transport. One paper focused exclusively on transportation barriers [60]. Fifteen papers described environmental barriers that included the education and literacy levels of participants, socioeconomic status and the challenges of poverty, physical accessibility and the availability of transport. One paper focused exclusively on transportation barriers [60]. Sociocultural considerations, including language barriers, were identified in one study as discouraging some participants from enrolling [43]. While altruism was a motivator for others to participate [64, 65]. Sociocultural considerations, including language barriers, were identified in one study as discouraging some participants from enrolling [43]. While altruism was a motivator for others to participate [64, 65]. A range of patient characteristics influencing enrolment were reported across seven papers, many related to prospective participants’ physical condition and age, disease progression, psychiatric comorbidities and other factors [40, 41, 43, 46, 48, 61–63]. A range of patient characteristics influencing enrolment were reported across seven papers, many related to prospective participants’ physical condition and age, disease progression, psychiatric comorbidities and other factors [40, 41, 43, 46, 48, 61–63]. Initiatives to support participation Table 4 reports on initiatives implemented by researchers to ultimately promote the participation of rural patients with cancer in CT. Two studies reported initiatives directed at rural patients [42, 46]. One of these implemented a patient navigation support service for underserved and ethnic minority participants [46], and the other modified a previously published patient decision aid for use in a rural context [42]. Farris et al. described the creation of a patient-informed tool with community stakeholders to increase awareness of CT in rural areas [49]. Table 4Initiatives to support participationStakeholderAuthorFocus of initiativeOutcomeCancer patientsPathak S [42]Adapting existing cancer CT decision aid (Cancer Research CHOICES DA) for rural patients (R-CHOICES DA) and testing it to assess its impact on knowledge and decision outcomesR-CHOICES DA did improve knowledge of cancer CT and increased patient certainty on whether they would take part in a CT. Following use of the modified DA, however, there were no significant changes to participants’ confidence in discussing CT with clinicians, their attitudes towards CT or their willingness to take part in cancer CT.Guadagnolo BA [46]Patients identified as American Indian in larger study were offered support of a patient navigator who had experience in providing culturally competent care. They were able to support patients throughout their treatment with support for issues like appointments, accommodation and social supports.All American Indian patients on CT accepted engagement with the patient navigator. Overall, the researchers found relatively higher American Indian participation rates for CT than reported elsewhere in other studies.Cancer patients & CliniciansFriedman DR [48]Patients attending a Veterans Affairs blood cancer service were referred to a Leukaemia & Lymphoma Society’s Clinical Trial Support Center (LLS CTSC), which supported them with CT education and patient navigation as a support.Thirty-three patients were referred to the LLS CTSC, and three of them ultimately enrolled on CT. The reasons the remaining patients did not enrol on CT included not meeting eligibility criteria and transport issues.Elliott TE [56]Evaluating to impact of an intervention for healthcare professionals on outcomes for rural cancer patientsFollowing introduction of the programme, travel for clinical care was significantly reduced in the intervention group of cancer patients, but no differences were noted in satisfaction with care, financial barriers or health-related quality of life were found with the non-intervention group.Community leaders & othersFarris P [49]Implementation of a codesigned research review strategy with community members that allows them to consider and endorse specific cancer CT opening in their community. Takes into account the ‘cultural landscape’ of the community.Researchers successfully piloted the research review strategy with a cancer early detection CT involving primary care and oncology.CliniciansEllis S [51]Developing an intervention to promote the referral of urology cancer patients to CT using implementation science approachDesigned the intervention using a recognized framework that seemed to be acceptable and appropriate for rural practices, with high ‘intention to adopt’ reported by clinicians.Community health workersCupertino AP [55]Developing and evaluating training on cancer and CT for rural community health workersPost the educational intervention, the community health workers’ levels of knowledge on various cancer and research topics had improved. Completion rates of the course and willingness to participate in future research were also reported as high. Initiatives to support participation One study by Ellis et al. reported on an educational initiative targeting clinicians serving rural areas to try to increase CT recruitment [51]. Elliott et al. also developed an educational package for clinicians to enhance knowledge and confidence in referring patients to cancer CT, but also looked at patient outcomes [56]. Community health workers were provided with education in an intervention by Cupertino et al. which focused on improving their knowledge on the fundamentals of cancer and treatment options, including research and CT [55]. Most participants were from ethnic minority backgrounds, enabling them to act as cultural mediators and health-system navigators [55]. Decision-making in clinical trials Four papers included focused on exploring the reasoning behind patient decisions on trial engagement. For example, Table 5 reports that Pathak et al. took the Cancer Research Choices Decision Aid (CHOICES) that had been created to assist with cancer CT recruitment and modified it for use by rural patients [42]. Table 5Decision makingStakeholderAuthorFocus of initiativeDecision makingPathak S [42]Adapting cancer CT decision aid for rural patients and testing to assess impact on knowledge and decision outcomesKrieger JL [57]Distributed cognition in cancer treatment decision making: an application of the DECIDE decision-making styles typologyExploring the decision making of rural cancer patients and their caregivers when engaging with cancer CTUnderstanding randomisation and uncertaintyKrieger JL [44]Exploring patients understanding of randomisation, treatment uncertainty and willingness to enrol in cancer CTUse of metaphorsKrieger JL [45]Last resort or roll of the die? Exploring the role of metaphors in cancer CT education among medically underserved populationsExploring older, low-income female patients’ understanding of cancer CT by examining metaphors used in clinical encounters Decision making Distributed cognition in cancer treatment decision making: an application of the DECIDE decision-making styles typology Exploring the decision making of rural cancer patients and their caregivers when engaging with cancer CT Last resort or roll of the die? Exploring the role of metaphors in cancer CT education among medically underserved populations Exploring older, low-income female patients’ understanding of cancer CT by examining metaphors used in clinical encounters Tailoring this tool to rural-dwelling patients did result in participants gaining high levels of knowledge about trials and high levels of certainty about choosing to enrol on trials, but its use did not lead to any significant change in patient attitudes towards trials or willingness to enrol on trials, however [42]. Krieger and colleagues have extensively studied cancer research in rural settings and have used their sustained engagement with patients from Appalachia to explore CT. Initially focusing on older, low-income women with cancer in Appalachia and their perceptions of CT, Krieger examined the metaphors patients used in describing trial participation [45]. As a result, she highlighted the need for improved communication by triallists and the avoidance of negative metaphors. In subsequent work, she explored the concepts of randomisation and uncertainty and distributed cognition, emphasising the role of family and caregivers in shared decision-making for treatment and trial participation [44, 57]. In summary, we explored the 27 papers examining the main characteristics and definitions utilised in the conduct of relevant research. We have applied a specific research lense to several of the papers to help us analyse the nuances of rural participant engagement with cancer CT. Discussion This scoping review aimed to examine the body of evidence around the recruitment of adults with cancer living in rural or remote areas to CT. The 27 papers identified by the systematic search were used to examine the definitions of rurality used, as well as the levers, barriers and initiatives related to the participation of rural patients in cancer clinical trials. We will discuss the major implications for the equitable recruitment of cancer patients from rural areas to appropriate high-quality clinical trials. The predominance of research conducted in the USA may reflect the relative size of its rural population, and potentially the documented cancer rates and inequities in cancer outcomes for these patients. It may also reflect the advanced clinical networks and research infrastructure that have been developed in rural areas of the country over many decades. Public bodies such as the National Cancer Institute (NCI), and not-for-profits like the American Cancer Society and cancer networks such as the National Comprehensive Cancer Network has done much to raise the profile of cancer, clinical advances and opportunities and ongoing research in that time. Surprisingly, no primary research from Europe was discovered; this may reflect the fact that majority of cancer CT there are industry rather than publicly funded, using established centres that tend to be in urban areas, making research analysing rural participation less likely [4]. It was also notable that only one paper from Canada and three from Australia were found to meet the criteria, as these are both countries in which rural healthcare is generally perceived to be well developed [67, 68]. They have similar favourable policy environments with the long‑standing availability of universal health coverage, decentralised healthcare governance structures and workforce policies targeted at rural and remote areas [69]. No papers from low- and middle-income countries were found, and this may reflect that the conduct of CT requires significant funding and dedicated research capacity [70]. It was also notable that only one paper explored the experiences of carers in relation to cancer CT [45]. We know that carers and family members have an important role in supporting affected cancer patients in their decision-making on starting and their adherence to trials [71, 72]. We expected more involvement from this key stakeholder group, particularly in the rural context where transport to and from trial centres may be reliant on them. We also noted that some authors focused on recruitment of very specific groups of participants, such as armed forces veterans living rurally with blood cancers [48]. and older-aged low-income rural dwelling women [45]. The narrow inclusion criteria in these studies could have implications for their generalisability. Only one paper by Guadagnolo et al. mentioned American Indians as a specific indigenous group being focused on in terms of their engagement, and this could be considered surprising given that they mainly live in rural areas of the USA [46]. It cannot be presumed that by living rurally, all patients will face significant travel distances to cancer centres, but most trial activity happens in specialist centres that tend to be in urban areas. Most trials will require patients to attend a series of in-person clinic visits to assess suitability and deliver treatment, making the distances that patients must travel from home an important consideration, with the time and financial costs involved [73]. Efforts have been made in the USA to bring cancer centre expertise closer to people in underserved communities, for example, the NCI Community Oncology Research Program (NCORP), which comprises a network of centres at sites in communities across the country. The term “clinical trial deserts” [48, p. 114] closely linked to the term “medical deserts” [74, p. 785] which Brînzac et al. defined as “areas where population healthcare needs are unmet partially or totally due to lack of adequate access or improper quality of healthcare services caused by insufficient human resources in health or facilities, long waiting times, disproportionate high costs of services or other socio-cultural barriers” [74, p. 785] applies to many rural areas. When you consider that basic health and cancer care infrastructure in certain rural areas is lacking [75, 76], it is not surprising that there are low levels of clinical research or trials taking place in those areas [77]. Some researchers have extrapolated the implications of these “clinical trial deserts” for population health and particular cancers, with one study estimating that around 40 million Americans lived in areas poorly served by gastrointestinal cancer CT in 2024. It is suggested that increased use of community hospital networks and telemedicine might help to address this inequity [78]. Our analysis of the ways rurality was classified illustrates the diverse approaches of author groups, even in the 23 papers from the USA. Many papers did not adopt any formal description of the rurality of participants; some used attendance at clinics located in rural areas as a proxy identifier for the rural status of patients, others mentioned that patients originated from predominantly rural regions or states, e.g. Appalachia, as an indicator of high likelihood of being rurally based. Both approaches, however, could have included participants who were not rural. In the USA, there are accepted rural designations, and the use of the RUCC in particular has been recommended for use over other indices. It has been described as the “standardly available in national cancer registries, can be matched to patients’ county of residence for local research, and it had the least amount of fluctuation of the indices analyzed” [79, p. 78]. Possible implications of not adopting a standardised approach to identifying rurality clearly have been highlighted previously by Smith et al. who noted that “repeating the same study with the same data but applying different definitions of rural and medically underserved may result in very different conclusions” [80, p. 7]. This could then have implications for service design and potential policy responses to gaps highlighted in rural health research [80, 81]. However, there are some doubts about an over-reliance on systematic geographical designation of rural participants, and there is acknowledgement that they were not created for health research [80, 82]. It is also worth noting that rural designation does not always align with an area being medically underserved, so there are nuances that need to be taken into account before embarking on research and when making follow-up practice or policy recommendations [80]. The Appalachian region of the USA features in three of the included papers, and it is frequently described as a region with marked inequity in health outcomes [83]. According to the Appalachian Community Cancer Alliance, the region’s population is more than 25 million inhabitants living in both rural and urban settings, and it includes all of West Virginia and parts of twelve other states. Significant challenges with persistent poverty, high rates of chronic diseases and addiction, infrastructure problems, limited access to healthcare and health literacy concerns are all recognised in the region [83, 84]. In 2017, it was noted that Appalachia’s cancer mortality was 10% higher than the national average, with rural areas of the region having more marked differences [83]. Use of the SEM as employed by Wells and Zebrack to explore a subset of the papers highlighted that many factors recognised as Social Determinants of Health by Dahlgren and Whitehead have a strong influence on rural cancer CT enrolment [38, 85]. These include living conditions, education, employment status, income levels and others, and they were acknowledged as barriers across all thirteen papers under the category of environment. When these wider societal issues are at play, it can be difficult for healthcare professionals and cancer clinicians to know where to begin to address these to try to improve CT participation. It is worth noting that cancer CT trials take place in the context of a wider health ecosystem, and clinicians, patients and other relevant stakeholders should be empowered to advocate for better living conditions and social supports for patients for them to be able to even consider participation. It is also not surprising that inTRApersonal and inTERpersonal factors were commonly cited; past experiences and health beliefs, and concerns had direct effects on patient decision-making when considering trial enrolment. The inTERpersonal domain considered the influence of other stakeholders and social networks on engagement of individual patients with trials; and hearing personal stories from others who had enrolled on trials in the past may help to answer some concerns. Many of these barriers have been discussed in the literature in the past, and rural cancer patients are no different [23]. CT are complex, and patients can struggle to fully understand their potential benefits and the steps involved in taking part [86, 87]. Initiatives to increase knowledge and understanding of trials for patients have shown varying levels of success [88]. The improvement of patient and public knowledge of CT, and cancer trials in particular, has been the focus of several bodies (e.g. NIH & NCI) in recent years with information campaigns on everything from the steps involved to personal stories from participants, including some from rural areas. The American Cancer Society has its own Access to Clinical Trials programme that provides similar information, including using videos for patients with limited literacy. Education for clinicians should include a basic understanding of cancer, cancer treatments, clinical research and cancer CT for these professionals to be able to advise patients. This could take place across the educational continuum from undergraduate to clinicians-in-training, to qualified specialist levels [89, 90]. The topic also lends itself well to interprofessional education for students and professional development, as much modern cancer care is delivered by multidisciplinary teams [91]. Digital tools for education may be of particular relevance to clinicians who are working in rural or remote settings. Taking the totality of these points into consideration, it is likely that marked underrepresentation of rural participants with cancer in research on clinical trials will persist unless fundamental changes are made to how trials are structured and delivered. This will have knock on effects on the generalisability and ‘real-world’ use of the evidence generated from trials. This may lead to an almost self-fulfilling loop of limited evidence being generated in rural settings, leading to limited understanding of the complexities and possible mitigation strategies, leading ultimately to cancer patients in these areas having less access to novel treatments and approaches. Strengths and limitations of this study There are several strengths and limitations in this research. Searches conducted were comprehensive, allowing us to provide analysis of a broad array of papers examining rurality and cancer CT engagement. The engagement of a team of four researchers to meet and regularly discuss any conflicts in screening or clarify any points of concern was also positive. Use of the SEM as adapted by Wells and Zebrack to analyse a subset of the papers to tease out the levers and barriers was a strength. Limitations included that we were only able to include papers published in English due to a lack of translation. The absence of an agreed international classification of rurality is a limitation, meaning we were often solely reliant on the author’s description of their included participants. There was also heterogeneity of many aspects of the papers included, making comparisons challenging. Using the SEM as adapted by Wells and Zebrack to analyse only a portion of the papers we included may result in the separation of identification of barriers and enablers from evidence of their modifiability and practical impact, possibly limiting the application of this research. Implications for policy, practice and further research This study highlights that living rurally brings significant challenges for potential participants in cancer CT. Distance and travel, while important, are not the only barriers to be unpacked in this context. Others include concerns about side effects, education and literacy challenges, and the patients physical condition and age. In terms of accurately defining rural status, an international agreement on a standardised way of defining it should be considered. The development of rural healthcare infrastructure, including staffing, cancer care infrastructure and the creation of research capacity at these rural sites, is vital for meaningful progress in making high-quality cancer CT more accessible for rural patients. Fostering the growth of collaborative research networks between major academic cancer centres in Europe and smaller rural health institutions may help improve coverage of CT also. Potential future research could include a specific focus on carers and family members of people with cancer and exploring the experiences of specific groups, such as indigenous or minority groups in rural settings. Training and education are required for stakeholders to try to overcome any preconceptions on CT engagement. Conclusions Cancer CT are vital for the evaluation of novel treatments and approaches. Rural populations have worse cancer outcomes, yet they are underrepresented in trials. This scoping review examined 27 papers identified as being relevant to the recruitment of patients from rural areas to cancer CT. The majority of these papers were from the USA, where rural cancer research appears to be more developed. There were no papers from Europe or low and middle-income country settings. Fourteen of the papers were quantitative, nine were qualitative, and four employed mixed methods. The definitions used by researchers to delineate rural participants from others varied, even in the USA where there is some degree of standardisation of definitions. The recruitment of cancer patients to CT is challenging and heavily dependent on healthcare and research infrastructure being in place in more peripheral locations to make it a viable option for participants to engage with trials. There are a variety of initiatives that have been employed to try to improve this engagement, as well as efforts to improve understanding of trials themselves. Unless there is a concerted effort made internationally to address the acknowledged challenges, the recruitment of rural-dwelling cancer patients to CT will not advance. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1: Additional File 1. Search Strategy. Supplementary Material 2: Additional File 2. Categorisation of levers and barriers. Supplementary Material 3: Related File 1. PRISMA Scoping Review checklist. Acknowledgements N/A. Abbreviations Clinical Trials United States of America United Kingdom Joanna Briggs Institute Public and Patient Involvement Rural–Urban Continuum Codes Rural-Urban Commuting Area United States National Cancer Institute Author contributions POD, RG, KR, PH, RC and NP conceived the basic idea for the research. POD and SD conducted early scoping searches, returning to RG, RC, NP and KR at intervals for discussion. SD and POD then conducted comprehensive searches. Screening was conducted by POD, RG, SD and DH. Any conflicts arising were discussed with the wider team at regular intervals. Analysis was then conducted by POD, DH, RG and SD, summarizing all data found and presenting it to the wider team for feedback. POD and SD drafted the manuscript for publication which was reviewed by RG, RC, KR, PH, DH and NP. All authors read and approved the final manuscript. Funding Cancer Trials Enhancement Award, Health Research Board of Ireland (https://www.hrb.ie/grant-approved/limerick-cancer-trials/). Data availability All data generated or analysed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate As the work was a desk-based review of published research, no research ethics committee approval was required. Consent for publication N/A Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1: Additional File 1. Search Strategy. Supplementary Material 2: Additional File 2. Categorisation of levers and barriers. Supplementary Material 3: Related File 1. PRISMA Scoping Review checklist. Data Availability Statement All data generated or analysed during this study are included in this published article and its supplementary information files.